Last reviewed · How we verify
Tafenoquine Control
At a glance
| Generic name | Tafenoquine Control |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Postpartum 8-aminoquinoline Breast Milk Study (PHASE2, PHASE3)
- Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis (PHASE2)
- FocaL Mass Drug Administration for Vivax Malaria Elimination (PHASE3)
- Tafenoquine in Patients With Mild to Moderate COVID-19 (PHASE2)
- Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine (PHASE3)
- Long-Term Safety Study of Tafenoquine (PHASE2)
- Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria (PHASE3)
- A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tafenoquine Control CI brief — competitive landscape report
- Tafenoquine Control updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI